Αρχική World News Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along... World News Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease Από Ogkologos - 22 Σεπτεμβρίου, 2025 596 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ΚΑΡΚΙΝΟΣ ΗΠΑΤΟΣ 10 Δεκεμβρίου, 2018 EMA Recommends Extension of Indications for Atezolizumab 28 Σεπτεμβρίου, 2020 Promoting Inclusion for LGBTQ+ People With Cancer: “Your Stories” Podcast 21 Σεπτεμβρίου, 2021 Girl’s New College Dorm Has Perfect View Of The Hospital Room... 30 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Let’s talk about HPV: 6 common questions answered Opinion: ‘Beating cancer means beating it for everyone’ New Safety Signal for Use of Ibrutinib in Combination with Rituximab... “White Bagging” Harmful to Patients, Requires Them to Use Insurance-Approved Formulary...